Progress in prostate cancer chemoprevention: modulators of promotion and progression 1 1The information in this report was generated from group discussion at the Prostate Cancer Think Tank in December 1998.
Urology, ISSN: 0090-4295, Vol: 58, Issue: 6, Page: 835-842
2001
- 22Citations
- 20Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations22
- Citation Indexes22
- 22
- CrossRef16
- Captures20
- Readers20
- 20
Review Description
Progress in chemopreventive agent development for prostate cancer is guided by identification of new molecular targets through high throughput functional genomic screens and empirical evidence derived from epidemiologic studies, experimental models, and unexpected results from randomized primary prevention trials. More than a dozen agent classes with potential for prostate cancer prevention are in clinical development, including natural products, with many more novel classes expected in the near future (epidermal growth factor receptor inhibitors, proteosome inhibitors, etc.). Suitable study cohorts for definitive prevention trials can be identified and represent potential therapeutic niches for new agent registrations. However, the failure to identify and validate noninvasive surrogate endpoints that predict cancer incidence reduction is a major rate-limiting step thwarting the design and conduct of efficient clinical prevention trials for prostate cancer and the active participation of the pharmaceutical industry.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0090429501014169; http://dx.doi.org/10.1016/s0090-4295(01)01416-9; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0035667260&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/11744441; https://linkinghub.elsevier.com/retrieve/pii/S0090429501014169; http://linkinghub.elsevier.com/retrieve/pii/S0090429501014169; http://api.elsevier.com/content/article/PII:S0090429501014169?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S0090429501014169?httpAccept=text/plain; http://dx.doi.org/10.1016/s0090-4295%2801%2901416-9; https://dx.doi.org/10.1016/s0090-4295%2801%2901416-9
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know